Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany
Authors not listed
Merck Sharp & Dohme LLC · 2010
Abstract
This is an observational, non-comparative, multicenter, open-label study. Participants will be treated with Raltegravir according to standard clinical practice, and monitored over a total period of 96 weeks. In an extension to the study (Amendment 1), a new cohort of aging participants (≥ 50 years) will be recruited and monitored over a total period of 48 weeks. Participants who stop taking Raltegravir before the end of the 96-week period or 48-week period, respectively, will be followed up for 3 months after discontinuing the drug. The primary objective is to determine the proportion of participants with a human immunodeficiency virus (HIV)-1 viral load \< 50 copies/mL after 48 weeks of treatment with Raltegravir.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-05-31 MST
Cite this
APA
Anonymous. (2010). A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany. <em>Merck Sharp & Dohme LLC</em>. https://clinicaltrials.gov/study/NCT01213316
Vancouver
Anonymous. A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany. Merck Sharp & Dohme LLC. 2010.
BibTeX
@misc{anon2010ANonin,
title = {A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany},
author = {Anonymous},
journal = {Merck Sharp & Dohme LLC},
year = {2010},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Celgene 2016
Open access · US-GOV
Retrospective Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
Bayer 2012
Open access · US-GOV
Special Drug Use Investigation of EYLEA for AMD
Shanghai Mental Health Center 2026
Open access · US-GOV
A Phase I, Open-Label, Single-Center, Frequency-Escalation Study of the Safety, Tolerability, and Preliminary Efficacy of Neural Stem Cell-Derived Exosomes in Patients With Moderate-to-Severe Early-Onset Alzheimer's Disease
Hangzhou PhecdaMed Co., Ltd. 2026
Open access · US-GOV
A Randomized, Double-Blind, Multicenter, Placebo Parallel-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of TJ0113 Capsule in the Treatment of Patients With Sarcopenia
Pamukkale University 2024
Open access · US-GOV
Turkish Validity and Reliability of the Social Frailty Index in the Older Adults
NeuroEM Therapeutics, Inc. 2019
Open access · US-GOV